Golidocitinib: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 06:44, 24 December 2024 editBoghog (talk \| contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,738 editsm →top: removed stray text← Previous edit		Latest revision as of 01:30, 26 December 2024 edit undoGraeme Bartlett (talk \| contribs)Administrators249,716 edits more ids
(2 intermediate revisions by the same user not shown)
Line 79:		Line 79:
	\| PubChemSubstance =		\| PubChemSubstance =
	\| IUPHAR_ligand =		\| IUPHAR_ligand =
	\| DrugBank =		\| DrugBank = DB18057
	\| ChemSpiderID =		\| ChemSpiderID = 71117616
	\| UNII = 3BY9Z3M34G		\| UNII = 3BY9Z3M34G
	\| KEGG = D12502		\| KEGG = D12502
Line 122:		Line 122:
	]		]
	]		]
			]
			]

	{{antineoplastic-drug-stub}}		{{antineoplastic-drug-stub}}

Latest revision as of 01:30, 26 December 2024

Pharmaceutical compound

Golidocitinib
Clinical data

Trade names	高瑞哲 (Gao Ruizhe)
Other names	AZD-4205, AZD4205, JAK1-IN-3
Legal status
Legal status	Rx in China
Identifiers
IUPAC name (2R)-N-pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
CAS Number	2091134-68-6
PubChem CID	126715380
DrugBank	DB18057
ChemSpider	71117616
UNII	3BY9Z3M34G
KEGG	D12502
ChEMBL	ChEMBL4577523
Chemical and physical data
Formula	C₂₅H₃₁N₉O₂
Molar mass	489.584 g·mol
3D model (JSmol)	Interactive image
SMILES C(C(=O)NC1=CC=CC2=C1NC=C2C3=NC(=NC=C3)NC4=CN(N=C4OC)C)N5CCN(CC5)C
InChI InChI=InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1 Key:CVCVOSPZEVINRM-MRXNPFEDSA-N

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Golidocitinib is classified as a Janus kinase inhibitor.

References

Keam SJ (October 2024). "Golidocitinib: First Approval". Drugs. 84 (10): 1319–1324. doi:10.1007/s40265-024-02089-2. PMID 39298087.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. (January 2024). "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study". The Lancet. Oncology. 25 (1): 117–125. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
Jin J, Zhang L, Zou L, Li Z, Wu H, Zhou K, et al. (2024). "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood. 144: 6368. doi:10.1182/blood-2024-211891.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: